204 related articles for article (PubMed ID: 25230940)
1. Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice.
Ondondo B; Abdul-Jawad S; Bridgeman A; Hanke T
Clin Vaccine Immunol; 2014 Nov; 21(11):1565-72. PubMed ID: 25230940
[TBL] [Abstract][Full Text] [Related]
2. Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.
Ondondo B; Brennan C; Nicosia A; Crome SJ; Hanke T
Vaccine; 2013 Nov; 31(47):5594-601. PubMed ID: 23831324
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.
Hayton EJ; Rose A; Ibrahimsa U; Del Sorbo M; Capone S; Crook A; Black AP; Dorrell L; Hanke T
PLoS One; 2014; 9(7):e101591. PubMed ID: 25007091
[TBL] [Abstract][Full Text] [Related]
4. Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
Bauer A; Podola L; Mann P; Missanga M; Haule A; Sudi L; Nilsson C; Kaluwa B; Lueer C; Mwakatima M; Munseri PJ; Maboko L; Robb ML; Tovanabutra S; Kijak G; Marovich M; McCormack S; Joseph S; Lyamuya E; Wahren B; Sandström E; Biberfeld G; Hoelscher M; Bakari M; Kroidl A; Geldmacher C
J Virol; 2017 Sep; 91(18):. PubMed ID: 28701395
[TBL] [Abstract][Full Text] [Related]
5. Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines.
Clutton G; Carpov A; Parks CL; Dean HJ; Montefiori DC; Hanke T
AIDS; 2014 Nov; 28(17):2495-504. PubMed ID: 25229267
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects.
Hancock G; Morón-López S; Kopycinski J; Puertas MC; Giannoulatou E; Rose A; Salgado M; Hayton EJ; Crook A; Morgan C; Angus B; Chen F; Yang H; Martinez-Picado J; Hanke T; Dorrell L
J Int AIDS Soc; 2017 May; 20(1):21171. PubMed ID: 28537062
[TBL] [Abstract][Full Text] [Related]
7. Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine.
Knudsen ML; Mbewe-Mvula A; Rosario M; Johansson DX; Kakoulidou M; Bridgeman A; Reyes-Sandoval A; Nicosia A; Ljungberg K; Hanke T; Liljeström P
J Virol; 2012 Apr; 86(8):4082-90. PubMed ID: 22318135
[TBL] [Abstract][Full Text] [Related]
8. Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques.
Rosario M; Borthwick N; Stewart-Jones GB; Mbewe-Mvula A; Bridgeman A; Colloca S; Montefiori D; McMichael AJ; Nicosia A; Quakkelaar ED; Drijfhout JW; Melief CJ; Hanke T
AIDS; 2012 Jan; 26(3):275-84. PubMed ID: 22095198
[TBL] [Abstract][Full Text] [Related]
9. DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.
Gorse GJ; Newman MJ; deCamp A; Hay CM; De Rosa SC; Noonan E; Livingston BD; Fuchs JD; Kalams SA; Cassis-Ghavami FL;
Clin Vaccine Immunol; 2012 May; 19(5):649-58. PubMed ID: 22398243
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
11. T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load.
Roshorm Y; Cottingham MG; Potash MJ; Volsky DJ; Hanke T
Eur J Immunol; 2012 Dec; 42(12):3243-55. PubMed ID: 22930183
[TBL] [Abstract][Full Text] [Related]
12. Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B.
Perdiguero B; Raman SC; Sánchez-Corzo C; Sorzano COS; Valverde JR; Esteban M; Gómez CE
Viruses; 2018 Aug; 10(8):. PubMed ID: 30104537
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice.
Jongwe TI; Chapman R; Douglass N; Chetty S; Chege G; Williamson AL
PLoS One; 2016; 11(7):e0159141. PubMed ID: 27427967
[TBL] [Abstract][Full Text] [Related]
14. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
15. Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.
Perdiguero B; Gómez CE; Nájera JL; Sorzano CO; Delaloye J; González-Sanz R; Jiménez V; Roger T; Calandra T; Pantaleo G; Esteban M
PLoS One; 2012; 7(10):e48524. PubMed ID: 23119046
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study).
Mothe B; Manzardo C; Sanchez-Bernabeu A; Coll P; Morón-López S; Puertas MC; Rosas-Umbert M; Cobarsi P; Escrig R; Perez-Alvarez N; Ruiz I; Rovira C; Meulbroek M; Crook A; Borthwick N; Wee EG; Yang H; Miró JM; Dorrell L; Clotet B; Martinez-Picado J; Brander C; Hanke T
EClinicalMedicine; 2019; 11():65-80. PubMed ID: 31312806
[TBL] [Abstract][Full Text] [Related]
17. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.
Goonetilleke N; Moore S; Dally L; Winstone N; Cebere I; Mahmoud A; Pinheiro S; Gillespie G; Brown D; Loach V; Roberts J; Guimaraes-Walker A; Hayes P; Loughran K; Smith C; De Bont J; Verlinde C; Vooijs D; Schmidt C; Boaz M; Gilmour J; Fast P; Dorrell L; Hanke T; McMichael AJ
J Virol; 2006 May; 80(10):4717-28. PubMed ID: 16641265
[TBL] [Abstract][Full Text] [Related]
18. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.
Rosario M; Bridgeman A; Quakkelaar ED; Quigley MF; Hill BJ; Knudsen ML; Ammendola V; Ljungberg K; Borthwick N; Im EJ; McMichael AJ; Drijfhout JW; Greenaway HY; Venturi V; Douek DC; Colloca S; Liljeström P; Nicosia A; Price DA; Melief CJ; Hanke T
Eur J Immunol; 2010 Jul; 40(7):1973-84. PubMed ID: 20468055
[TBL] [Abstract][Full Text] [Related]
19. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.
Borthwick N; Ahmed T; Ondondo B; Hayes P; Rose A; Ebrahimsa U; Hayton EJ; Black A; Bridgeman A; Rosario M; Hill AV; Berrie E; Moyle S; Frahm N; Cox J; Colloca S; Nicosia A; Gilmour J; McMichael AJ; Dorrell L; Hanke T
Mol Ther; 2014 Feb; 22(2):464-475. PubMed ID: 24166483
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
Hanke T; Blanchard TJ; Schneider J; Ogg GS; Tan R; Becker M; Gilbert SC; Hill AV; Smith GL; McMichael A
J Gen Virol; 1998 Jan; 79 ( Pt 1)():83-90. PubMed ID: 9460927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
